Showing results (41-50 of 314) with videos related to

Sort By:
Pageof 32
Arthritis and Rheumatism|September 2, 2008
The importance of reporting disease activity states in rheumatoid arthritis clinical trialsDaniel Aletaha, Julia Funovits, Josef S Smolen
Nature Reviews. Rheumatology|March 14, 2012
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?Josef S Smolen, Daniel Aletaha, Kurt Redlich
Arthritis Research & Therapy|February 22, 2014
Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costsHelga Radner, Josef S Smolen, Daniel Aletaha
Arthritis & Rheumatology (Hoboken, N.J.)|October 4, 2016
Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End PointsMichael E Mack, Elizabeth Hsia, Daniel Aletaha
Annals of the Rheumatic Diseases|January 17, 2014
Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trialsDaniel Aletaha, Farideh Alasti, Josef S Smolen
Annals of the Rheumatic Diseases|June 28, 2012
Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitionsPaul Studenic, Josef S Smolen, Daniel Aletaha
Lancet (London, England)|May 10, 2016
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Iain B McInnes
Rheumatology (Oxford, England)|June 26, 2026
Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trialsVictoria Konzett, Andreas Kerschbaumer, Laurenz Willmann, et al.
Best Practice & Research. Clinical Rheumatology|December 14, 2004
Therapeutic strategies in early rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Klaus P Machold
BMC Musculoskeletal Disorders|April 25, 2009
Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agentsAnders Gülfe, Daniel Aletaha, Tore Saxne, et al.
Pageof 32